ZOWALL CONSULTING HEALTH ECONOMICS & OUTCOMES RESEARCH

Zowall H, Brewer C, Deutsch A. Modeling of Risks and Benefits of Lung Cancer Screening Strategies using Low-Dose Helical CT (LDCT) Technology in Canada. Value in Health 11/2015; 18(7), A372–A373. (Download PDF - 1,129KB)

Zowall H, Brewer C, Deutsch A. Projected Cost Savings of Introducing Fecal Microbiota Transplant Treatment for Clostridium Difficile Infection in Canada. Value in Health 05/2015; 18(3):A238. (Download PDF - 1,051KB)

Zowall H, Brewer C, Deutsch A. Cost-Effectiveness of Fecal Microbiota Transplant in Treating Clostridium Difficile Infection in Canada. Value in Health 11/2014; 17(7):A676. (Download PDF - 61KB)

Zowall H, Brewer C, Deutsch A. A model of clostridium difficile infection: dynamic transmission between hospitals, long-term care facilities and communities. Value in Health 05/2014; 17(3):A280-A281. (Download PDF - 112KB)

Zowall H, Brewer C, Deutsch A. An online patient-oriented radiation risk assessment tool to project cancer risk following exposure to low ionizing radiation in Canada. Value in Health 05/2014; 17(3):A100.(Download PDF - 144KB)

Zowall H, Brewer C, Deutsch A. A comparison of medical computed tomographic utilization and potential related cancer risks in the United States and in Canada. Value in Health Vol. 16, 2013 May, Issue 3, Page A150. (Download PDF - 65KB)

Zowall H, Brewer C, Deutsch A. Trends in Computed Tomography Use in Canada: Low-Dose Ionizing Radiation and the Potential Related Cancer Risk. Value in Health Vol. 15, 2012 November, Issue 7, Page A436. (Download PDF - 69KB)

Zowall H, Brewer C, Deutsch A. Managing the Risk of Exposure to Low-Ionizing Radiation in Canada: A Population Model. Value in Health Vol. 15, 2012 June, Issue 4, Page A233. (Download PDF - 67KB)

Zowall H, Brewer C, Deutsch A. Public Funding for Infertility Treatments in Canada: Eligibility and Demand for IVF in Canada. Value in Health Vol. 15, 2012 June, Issue 4, Page A196. (Download PDF - 68KB)

Zowall H, Brewer C. Are Older Mothers More prone to Having Children with Disabilities? Lifetime Disability Outcomes Versus Multiple Birth Reductions Arising from In-Vitro Fertilization (IVF) Treatments in Canada. Value in Health Vol. 14, 2011 November, Issue 7, Page A408. (Download PDF - 57KB)

Zowall H, Brewer C. The impact of long-term disability costs arising from in-vitro fertilization (IVF) treatment: the cost-effectiveness analysis of reducing multiple births. Value in Health Vol. 14, 2011 May, Issue 3, Page A108. (Download PDF - 57KB)

Zowall H, Cairns JA, Brewer C, Lamping DL, Gedroyc WMW, Regan L. Cost-effectiveness of magnetic resonance-guided ultrasound surgery for treatment of uterine fibroids. BJOG 2008 April; Volume 115, Issue 5, 653-662. (Download PDF - 231KB)

Moe Gordon W, Howlett Jonathan, Januzzi James L, Zowall H, N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. Circulation. 2007;115:3103-3110. (Download PDF - 314KB)

Grover SA, Coupal L, Zowall H. Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors, What Are the Benefits of Avoiding Blood Pressure Destabilization? Hypertension. 2005;45:92. (Download PDF - 231KB)

Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS. 2004 Dec 3;18(18):2411-8. (Download PDF - 118KB).

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L. The importance of indirect costs in primary cardiovascular disease prevention: Can we save lives and money with statins? Arch Intern Med 2003;163:333-339. (Download PDF - 96KB)

Zowall H, Grover SA. Costs of dyslipidemia. Future Drugs: Expert Review of Pharmacoeconomics & Outcomes Research June 2003, Vol. 3, No. 3, Pages 273-281. (Download PDF - 203KB)

Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DRJ. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50. (Download PDF - 1200KB)

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:987-92. (Download PDF - 218KB)

Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:977-83. (Download PDF - 243KB)

Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-727. (Download PDF - 70KB)

Grover SA, Coupal L, Paquet S, Zowall H. The cost-effectiveness of HMG-CoA reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600. (Download PDF - 102KB)

Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-662. (Download PDF - 284KB)

Hamilton V, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273(13):1032-1038. (Download PDF - 452KB)